Podcast Episodes
Back to Search359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects
We invite STAT’s senior writer for infectious diseases, Helen Branswell, and Washington correspondent Chelsea Cirruzzo on to the podcast to discuss the latest news at the CDC. The agency is in the sp…
Published on 2 months, 2 weeks ago
358: FDA's gene therapy turmoil, and an alternative model for funding research
We discuss the tragic news that a second teenage boy with Duchenne muscular dystrophy died after taking Sarepta Therapeutics' gene therapy, raising renewed questions about the FDA's standards for app…
Published on 2 months, 3 weeks ago
357: The upheaval of CDC's vaccine panel, and drug pricing confusion
First, we chat about how pharma companies still don’t have much clarity on Trump’s most-favored nation drug pricing policy, biotech’s next big takeout target, and more. Then we bring on Kathryn Edwar…
Published on 2 months, 4 weeks ago
356: An AI experiment at the FDA & Novo trailing in the obesity drug race
The FDA has rolled out an internal AI tool called Elsa that, unlike its namesake Disney character, can’t seem to let go of mistakes. Our colleague Brittany Trang joins to explain. And it’s always a f…
Published on 3 months ago
355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview
The American Society of Clinical Oncology, or ASCO, kicks off its annual meeting this weekend in Chicago. We discuss what to watch at the meeting. Then, STAT’s infectious disease reporter Helen Brans…
Published on 3 months, 1 week ago
354: Uncertainty in CRISPR world and the start of more M&A
We chat about M&A deals picking up, leadership changes at Novo, and recent FDA advisory committee meetings for cancer drugs. We also bring on STAT reporter Jason Mast to talk about the latest researc…
Published on 3 months, 2 weeks ago
353: Trump's drug-pricing plan and a potential Theranos 2.0
We chat about the mixed sentiment in biotech markets these days and a new blood-testing company formed by Elizabeth Holmes' husband. We also bring on STAT's D.C. correspondent Daniel Payne to talk ab…
Published on 3 months, 3 weeks ago
352: A firebrand takes oversight of vaccines, gene therapies
Matt Herper joins Adam and Allison to examine Prasad's appointment and the band of outsiders now in charge of U.S. health agencies. He and Adam debate just how disruptive Prasad's tenure could be.
Published on 4 months ago
351: It's gonna be May (in biotech)
On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong drug launches, and Eli Lilly’s PBM problem.
The first 100 days of the Trump …
Published on 4 months, 1 week ago
350: Pharma tariffs, and a 'sunshine day' for biotech stocks
How did Ireland become a hotspot for pharmaceutical manufacturing? What are the products that will come out of Flagship's latest startup centered around "preemptive medicine"? And who among the co-ho…
Published on 4 months, 2 weeks ago